# Biosimilars
Keywords: biosimilars, biologics, healthcare, cost savings, patient access, innovation, adverse events, Biogen, Samsung Bioepis

> This page provides information about Biogen's commitment to biosimilars, highlighting their role in reducing healthcare costs, improving patient access, and fostering innovation. It also includes details on adverse event reporting and Biogen's collaboration with Samsung Bioepis.

## Details
- [Biosimilars](#): Biogen emphasizes its 40 years of experience with biologics and its dedication to biosimilars, which offer benefits like cost savings and sustainable access to therapies.
- [Healthcare Innovation](#): Biosimilars are presented as a way to alleviate the burden on healthcare systems, ensuring future innovation and expanded treatment options for patients and physicians.
- [Adverse Event Reporting](#): Instructions are provided for reporting adverse events in the UK and Ireland, including contact details for Biogen and Samsung Bioepis.
- [Immunology](#): A dedicated section on immunology biosimilars, highlighting their role in addressing unmet medical needs and improving patient outcomes.